Ifosfamide in advanced/disseminated breast cancer

R. Sorio, D. Lombardi, S. Spazzapan, N. La Mura, G. Tabaro, A. Veronesi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Ifosfamide is an alkylating agent active in various tumor types including breast cancer. The availability of mesna (sodium 2-mercaptoethanesulfonate) has increased its safety, avoiding the main dose-limiting side effect, urotoxicity. Interesting activity as a single agent, with response rates ranging from 7 to 30%, is reported in pretreated patients; more attractive data derived from phase II studies on ifosfamide combined with drugs known to be active in advanced breast cancer show response rates always over 35%. This review has taken in consideration papers published after 1995 and available on PubMed medline: the data indicate a potential usefulness of ifosfamide in the clinical management of advanced breast cancer, even if the exact therapeutic role of the drug in this setting should be derived from randomized studies not yet available.

Original languageEnglish
Pages (from-to)55-58
Number of pages4
JournalOncology
Volume65
Issue numberSUPPL. 2
DOIs
Publication statusPublished - 2003

Fingerprint

Ifosfamide
Breast Neoplasms
Mesna
Alkylating Agents
PubMed
Pharmaceutical Preparations
Safety
Neoplasms
Therapeutics

Keywords

  • Breast cancer
  • Ifosfamide
  • Mesna
  • Urotoxicity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sorio, R., Lombardi, D., Spazzapan, S., La Mura, N., Tabaro, G., & Veronesi, A. (2003). Ifosfamide in advanced/disseminated breast cancer. Oncology, 65(SUPPL. 2), 55-58. https://doi.org/10.1159/000073360

Ifosfamide in advanced/disseminated breast cancer. / Sorio, R.; Lombardi, D.; Spazzapan, S.; La Mura, N.; Tabaro, G.; Veronesi, A.

In: Oncology, Vol. 65, No. SUPPL. 2, 2003, p. 55-58.

Research output: Contribution to journalArticle

Sorio, R, Lombardi, D, Spazzapan, S, La Mura, N, Tabaro, G & Veronesi, A 2003, 'Ifosfamide in advanced/disseminated breast cancer', Oncology, vol. 65, no. SUPPL. 2, pp. 55-58. https://doi.org/10.1159/000073360
Sorio R, Lombardi D, Spazzapan S, La Mura N, Tabaro G, Veronesi A. Ifosfamide in advanced/disseminated breast cancer. Oncology. 2003;65(SUPPL. 2):55-58. https://doi.org/10.1159/000073360
Sorio, R. ; Lombardi, D. ; Spazzapan, S. ; La Mura, N. ; Tabaro, G. ; Veronesi, A. / Ifosfamide in advanced/disseminated breast cancer. In: Oncology. 2003 ; Vol. 65, No. SUPPL. 2. pp. 55-58.
@article{5890fd1c0e8c4428a34132001fb106ea,
title = "Ifosfamide in advanced/disseminated breast cancer",
abstract = "Ifosfamide is an alkylating agent active in various tumor types including breast cancer. The availability of mesna (sodium 2-mercaptoethanesulfonate) has increased its safety, avoiding the main dose-limiting side effect, urotoxicity. Interesting activity as a single agent, with response rates ranging from 7 to 30{\%}, is reported in pretreated patients; more attractive data derived from phase II studies on ifosfamide combined with drugs known to be active in advanced breast cancer show response rates always over 35{\%}. This review has taken in consideration papers published after 1995 and available on PubMed medline: the data indicate a potential usefulness of ifosfamide in the clinical management of advanced breast cancer, even if the exact therapeutic role of the drug in this setting should be derived from randomized studies not yet available.",
keywords = "Breast cancer, Ifosfamide, Mesna, Urotoxicity",
author = "R. Sorio and D. Lombardi and S. Spazzapan and {La Mura}, N. and G. Tabaro and A. Veronesi",
year = "2003",
doi = "10.1159/000073360",
language = "English",
volume = "65",
pages = "55--58",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Ifosfamide in advanced/disseminated breast cancer

AU - Sorio, R.

AU - Lombardi, D.

AU - Spazzapan, S.

AU - La Mura, N.

AU - Tabaro, G.

AU - Veronesi, A.

PY - 2003

Y1 - 2003

N2 - Ifosfamide is an alkylating agent active in various tumor types including breast cancer. The availability of mesna (sodium 2-mercaptoethanesulfonate) has increased its safety, avoiding the main dose-limiting side effect, urotoxicity. Interesting activity as a single agent, with response rates ranging from 7 to 30%, is reported in pretreated patients; more attractive data derived from phase II studies on ifosfamide combined with drugs known to be active in advanced breast cancer show response rates always over 35%. This review has taken in consideration papers published after 1995 and available on PubMed medline: the data indicate a potential usefulness of ifosfamide in the clinical management of advanced breast cancer, even if the exact therapeutic role of the drug in this setting should be derived from randomized studies not yet available.

AB - Ifosfamide is an alkylating agent active in various tumor types including breast cancer. The availability of mesna (sodium 2-mercaptoethanesulfonate) has increased its safety, avoiding the main dose-limiting side effect, urotoxicity. Interesting activity as a single agent, with response rates ranging from 7 to 30%, is reported in pretreated patients; more attractive data derived from phase II studies on ifosfamide combined with drugs known to be active in advanced breast cancer show response rates always over 35%. This review has taken in consideration papers published after 1995 and available on PubMed medline: the data indicate a potential usefulness of ifosfamide in the clinical management of advanced breast cancer, even if the exact therapeutic role of the drug in this setting should be derived from randomized studies not yet available.

KW - Breast cancer

KW - Ifosfamide

KW - Mesna

KW - Urotoxicity

UR - http://www.scopus.com/inward/record.url?scp=0242288535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242288535&partnerID=8YFLogxK

U2 - 10.1159/000073360

DO - 10.1159/000073360

M3 - Article

C2 - 14586149

AN - SCOPUS:0242288535

VL - 65

SP - 55

EP - 58

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - SUPPL. 2

ER -